Tag: programmed cell death protein 1 (PD-1)

1. Atezolizumab significantly increased overall survival compared to platinum-based combination chemotherapy in participants with untreated metastatic non-small-cell lung cancer (NSCLC) and high programmed death 1 ligand (PD-L1) expression. 2. Atezolizumab was associated with longer progression-free survival compared to platinum-based combination chemotherapy. Evidence Rating Level: 1 (Excellent) Study Rundown: The first line-treatment for...
Pembrolizumab is a monoclonal antibody against programmed cell death protein 1 (PD-1). Previous studies have shown that pembrolizumab is effective in prolonging survival in advanced non-small-cell lung cancer (NSCLC) with a PD1-ligand (PD-L1) tumor proportion score (TPS) of 50% or greater. In this randomized, open-label, phase 3 study, pembrolizumab...
Association of Racial Disparities With Access to Kidney Transplant After the Implementation of the New Kidney Allocation System There are many reasons why a patient may be made inactive on the kidney transplant waiting list, including psychosocial or financial issues or medical comorbidities. This has important implications for a patient’s...